Last reviewed · How we verify
Placebo for Glimepiride
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in clinical trials for Type 2 Diabetes Mellitus (as comparator to Glimepiride).
At a glance
| Generic name | Placebo for Glimepiride |
|---|---|
| Sponsor | Theracos |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to measure the effect of an active drug against baseline or psychological expectation. In this case, it serves as a comparator to Glimepiride, a sulfonylurea that stimulates pancreatic beta cells to release insulin. Any observed benefit from placebo would be attributable to the placebo effect rather than direct drug action.
Approved indications
- Control arm in clinical trials for Type 2 Diabetes Mellitus (as comparator to Glimepiride)
Common side effects
Key clinical trials
- Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes (PHASE3)
- Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction. (PHASE3)
- Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes (NA)
- Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus (PHASE3)
- Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea (PHASE4)
- SGLT2 Inhibition and Left Ventricular Mass (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Glimepiride CI brief — competitive landscape report
- Placebo for Glimepiride updates RSS · CI watch RSS
- Theracos portfolio CI